IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9315489 B1

PDFFull Text
Date of Patent:
Apr. 19, 2016

Filed:

May. 09, 2013

Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1

Applicants:

Pascal Furet, Thann, FR;

Robert Martin Grotzfeld, Ettingen, CH;

Wolfgang Jahnke, Lorrach, DE;

Darryl Brynley Jones, Basel, CH;

Paul William Manley, Arlesheim, CH;

Andreas Marzinzik, Weil, DE;

Saliha Moussaoui, Bartenheim, FR;

Xavier Francois Andre Pelle, Kembs, FR;

Bahaa Salem, Basel, CH;

Joseph Schoepfer, Riehen, CH;

Inventors:

Pascal Furet, Thann, FR;

Robert Martin Grotzfeld, Ettingen, CH;

Wolfgang Jahnke, Lorrach, DE;

Darryl Brynley Jones, Basel, CH;

Paul William Manley, Arlesheim, CH;

Andreas Marzinzik, Weil, DE;

Saliha Moussaoui, Bartenheim, FR;

Xavier Francois Andre Pelle, Kembs, FR;

Bahaa Salem, Basel, CH;

Joseph Schoepfer, Riehen, CH;

Assignee:

Novartis AG, Basel, CH;

Attorney:

Scott W. Reid

Primary Examiner:

Deepak Rao

Int. Cl.
CPC ...
C07D 401/04 (2006.01); A61K 31/4427 (2006.01); C07D 403/04 (2006.01); C07D 213/81 (2006.01); C07D 213/85 (2006.01); C07D 317/60 (2006.01); C07D 231/12 (2006.01); C07D 233/38 (2006.01); C07D 233/54 (2006.01); C07D 239/26 (2006.01); C07D 239/30 (2006.01); C07D 239/34 (2006.01); C07D 407/14 (2006.01); C07D 241/12 (2006.01); C07D 241/20 (2006.01); C07D 277/22 (2006.01); A61K 31/381 (2006.01); A61K 31/4025 (2006.01); A61K 31/4418 (2006.01); A61K 31/4965 (2006.01); A61K 31/505 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); C07D 333/38 (2006.01);
U.S. Cl.
CPC ...
C07D 403/04 (2013.01); A61K 31/381 (2013.01); A61K 31/4025 (2013.01); A61K 31/4418 (2013.01); A61K 31/4965 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 213/81 (2013.01); C07D 213/85 (2013.01); C07D 231/12 (2013.01); C07D 233/38 (2013.01); C07D 233/54 (2013.01); C07D 239/26 (2013.01); C07D 239/30 (2013.01); C07D 239/34 (2013.01); C07D 241/12 (2013.01); C07D 241/20 (2013.01); C07D 277/22 (2013.01); C07D 317/60 (2013.01); C07D 333/38 (2013.01); C07D 401/04 (2013.01); C07D 407/14 (2013.01);
Abstract

The present invention relates to compounds of formula I: in which Y, Y, Y, Y, Y, R, R, Rand Rare defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.

Find Patent Forward Citations

Loading…